(Q36797844)

16 August 2017

6 references

2 November 2019

11 November 2019

12 November 2019

24 July 2020

5 July 2022

29 July 2022

Hybrid Therapy Regimen for Helicobacter Pylori Eradication (English)

1 reference

Helicobacter pylori infectious disease

16 August 2017

1 reference

2 November 2019

1 reference

11 November 2019

1 reference

12 November 2019

1 reference

1 reference

24 July 2020

1 reference

Zhi-Qiang Song

1

1 reference

16 August 2017

Jian Liu

series ordinal

2

1 reference

16 August 2017

Li-Ya Zhou

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 January 2016

1 reference

16 August 2017

20 April 2016

6 references

2 November 2019

11 November 2019

12 November 2019

24 July 2020

5 July 2022

29 July 2022

Chinese Medical Journal

4 references

16 August 2017

24 July 2020

5 July 2022

29 July 2022

129

1 reference

16 August 2017

8

1 reference

16 August 2017

992-999

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

16 August 2017

6 references

2 November 2019

11 November 2019

12 November 2019

24 July 2020

5 July 2022

Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis

29 July 2022

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Optimal therapy for Helicobacter pylori infections

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Helicobacter pylori treatment in the era of increasing antibiotic resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

The sequential therapy regimen for Helicobacter pylori eradication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4831536

A report card to grade Helicobacter pylori therapy

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27064046

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4103/0366-6999.179803

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

27064046

1 reference